ATE517638T1 - Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln - Google Patents
Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mittelnInfo
- Publication number
- ATE517638T1 ATE517638T1 AT04737253T AT04737253T ATE517638T1 AT E517638 T1 ATE517638 T1 AT E517638T1 AT 04737253 T AT04737253 T AT 04737253T AT 04737253 T AT04737253 T AT 04737253T AT E517638 T1 ATE517638 T1 AT E517638T1
- Authority
- AT
- Austria
- Prior art keywords
- preparations
- diagnostic agents
- administering therapeutic
- targeting
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44435703P | 2003-01-31 | 2003-01-31 | |
| PCT/US2004/002768 WO2004074434A2 (en) | 2003-01-31 | 2004-02-02 | Methods and compositions for administering therapeutic and diagnostic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517638T1 true ATE517638T1 (de) | 2011-08-15 |
Family
ID=32908405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04737253T ATE517638T1 (de) | 2003-01-31 | 2004-02-02 | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7534431B2 (de) |
| EP (1) | EP1587550B1 (de) |
| JP (1) | JP4874090B2 (de) |
| CN (1) | CN1767860A (de) |
| AT (1) | ATE517638T1 (de) |
| AU (1) | AU2004213752B2 (de) |
| CA (1) | CA2514277C (de) |
| IL (1) | IL169896A (de) |
| MX (1) | MXPA05008222A (de) |
| WO (1) | WO2004074434A2 (de) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| EP2865688A1 (de) * | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung |
| CA2514277C (en) * | 2003-01-31 | 2015-01-20 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| JP2007524412A (ja) * | 2004-01-22 | 2007-08-30 | イムノメディクス， インコーポレイテッド | 葉酸コンジュゲートおよびコンプレックス |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| WO2006114115A1 (de) | 2005-04-26 | 2006-11-02 | Trion Pharma Gmbh | Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs |
| US20070128116A1 (en) * | 2005-07-27 | 2007-06-07 | Wang Zheng J | Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs |
| JP2009503115A (ja) * | 2005-08-03 | 2009-01-29 | アールキュー バイオサイエンス インク | ＩｇＡ及びＩｇＭを媒介する腎臓症を診断するための方法及び組成物 |
| US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| KR20080100353A (ko) * | 2006-02-01 | 2008-11-17 | 더 존스 홉킨스 유니버시티 | 신생물성 또는 감염성 질환의 면역예방 또는 면역요법용 폴리펩티드-핵산 접합체 |
| CA2651285C (en) * | 2006-05-15 | 2014-08-19 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| AU2007296055A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008124660A2 (en) * | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| CA2695385A1 (en) * | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| EP2237684A2 (de) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonisten für antimikrobielle peptidsysteme |
| US8475763B2 (en) * | 2008-10-09 | 2013-07-02 | Actis, Ltd. | Method of determining the course of treatment for a patient having adenocarcinoma |
| US8512728B2 (en) * | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
| CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| IN2012DN03177A (de) * | 2009-12-04 | 2015-09-25 | Immunomedics Inc | |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| US10167319B2 (en) * | 2010-05-29 | 2019-01-01 | Ben-Gurion University Of Negev Research & Development Authority | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| CN106620693A (zh) | 2010-09-03 | 2017-05-10 | 艾伯维施特姆森特克斯有限责任公司 | 新型调节剂及使用方法 |
| US10702614B2 (en) | 2011-02-15 | 2020-07-07 | Albert Einstein College Of Medicine | Radiobacteria for therapy of cancer |
| US20130231583A1 (en) * | 2012-03-02 | 2013-09-05 | Donna Rekkerth | Methods and Compositions for Injection Delivery |
| CN104363922B (zh) | 2012-06-14 | 2017-06-30 | 微仙美国有限公司 | 聚合物治疗组合物 |
| HUE045435T2 (hu) | 2012-10-12 | 2019-12-30 | Medimmune Ltd | Pirrolobenzodiazepinek és konjugátumaik |
| KR102275634B1 (ko) | 2012-10-15 | 2021-07-08 | 마이크로벤션, 인코포레이티드 | 폴리머 치료 조성물 |
| JP6064601B2 (ja) | 2013-01-09 | 2017-01-25 | オムロンヘルスケア株式会社 | 超音波式吸入器用の薬液槽および薬液パック |
| EP2945645B8 (de) * | 2013-01-17 | 2019-10-23 | Sylvain Tourel | Selektives zelltod-induzierendes binäres enzymsystem |
| US8877202B2 (en) * | 2013-02-07 | 2014-11-04 | Immunomedics, Inc. | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| JP6270264B2 (ja) * | 2014-02-04 | 2018-01-31 | 株式会社ミツトヨ | 情報処理装置、情報処理方法、プログラム、測定装置、及び測定方法 |
| CN106029098A (zh) | 2014-02-25 | 2016-10-12 | 免疫医疗公司 | 人源化rfb4抗cd22抗体 |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| CN106999517A (zh) | 2014-10-07 | 2017-08-01 | 免疫医疗公司 | 抗体‑药物缀合物的新辅助剂用途 |
| EP3286224A4 (de) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen |
| US10126298B2 (en) | 2015-05-04 | 2018-11-13 | Arman Nabatian | Hydrogels containing embedded substrates for targeted binding of molecules |
| CN107614515B (zh) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
| SI3316885T1 (sl) | 2015-07-01 | 2021-09-30 | Immunomedics, Inc. | Imunokonjugati protitelo-SN-38 z linkerjem CL2A |
| NZ739721A (en) | 2015-08-07 | 2019-09-27 | Imaginab Inc | Antigen binding constructs to target molecules |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| US11007272B1 (en) * | 2016-10-07 | 2021-05-18 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| WO2018085050A1 (en) * | 2016-11-03 | 2018-05-11 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for imaging tissues and tumors |
| EP3375871A1 (de) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Enzymsystem zur auslösung von selektivem zelltod |
| EP3606964A4 (de) | 2017-04-03 | 2020-12-09 | Immunomedics, Inc. | Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie |
| US10576182B2 (en) | 2017-10-09 | 2020-03-03 | Microvention, Inc. | Radioactive liquid embolic |
| JP2021524449A (ja) | 2018-05-23 | 2021-09-13 | アーデーセー セラピューティクス ソシエテ アノニム | 分子アジュバント |
| WO2019232227A1 (en) * | 2018-05-30 | 2019-12-05 | Zap Surgical Systems, Inc. | Radiosurgical neuromodlation close to critical structures |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US4150149A (en) | 1976-11-29 | 1979-04-17 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Method and means for the early detection and diagnosis of certain types of cancers |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| EP0643583B1 (de) | 1992-05-06 | 2000-07-26 | Immunomedics, Inc. | Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren |
| US5914312A (en) * | 1992-06-09 | 1999-06-22 | Neorx Corporation | Pretargeting methods and compounds |
| US5608060A (en) * | 1992-06-09 | 1997-03-04 | Neorx Corporation | Biotinidase-resistant biotin-DOTA conjugates |
| US5846741A (en) | 1992-08-21 | 1998-12-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
| US6120768A (en) | 1993-05-17 | 2000-09-19 | Immunomedics, Inc. | Dota-biotin derivatives |
| JPH09506106A (ja) * | 1993-12-07 | 1997-06-17 | ネオルクス コーポレーション | プレターゲティング方法及び化合物 |
| ATE306930T1 (de) * | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US5965115A (en) | 1997-11-05 | 1999-10-12 | The Procter & Gamble Company | Personal care compositions |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| ATE460946T1 (de) * | 1998-06-22 | 2010-04-15 | Immunomedics Inc | Gebrauch von bispezifischen antikörpern in diagnose und therapie |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| ATE499115T1 (de) * | 1998-09-18 | 2011-03-15 | Immunomedics Inc | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| KR20040091616A (ko) * | 2001-12-26 | 2004-10-28 | 이뮤노메딕스, 인코오포레이티드 | Ｖｈ 및 ｖｌ 도메인으로부터 멀티특이성, 다원자가제제를 제조하는 방법 |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| EP2865688A1 (de) * | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalisierung von Anti-CD74-Antikörpern und Verfahren zur Verwendung |
| US20040018557A1 (en) * | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| DE60325184D1 (de) * | 2002-03-01 | 2009-01-22 | Immunomedics Inc | Rs7 antikörper |
| US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| JP4083507B2 (ja) * | 2002-08-28 | 2008-04-30 | セイコーインスツル株式会社 | 半導体装置の製造方法 |
| CA2514277C (en) * | 2003-01-31 | 2015-01-20 | Immunomedics, Inc. | Methods and compositions for administering therapeutic and diagnostic agents |
| EP1633773A4 (de) * | 2003-06-13 | 2010-10-20 | Immunomedics Inc | D-aminosäurepeptide |
| WO2006107617A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
-
2004
- 2004-02-02 CA CA2514277A patent/CA2514277C/en not_active Expired - Fee Related
- 2004-02-02 JP JP2006503216A patent/JP4874090B2/ja not_active Expired - Fee Related
- 2004-02-02 MX MXPA05008222A patent/MXPA05008222A/es active IP Right Grant
- 2004-02-02 EP EP04737253A patent/EP1587550B1/de not_active Expired - Lifetime
- 2004-02-02 US US10/768,707 patent/US7534431B2/en not_active Expired - Fee Related
- 2004-02-02 WO PCT/US2004/002768 patent/WO2004074434A2/en active Application Filing
- 2004-02-02 CN CNA2004800090642A patent/CN1767860A/zh active Pending
- 2004-02-02 AU AU2004213752A patent/AU2004213752B2/en not_active Ceased
- 2004-02-02 AT AT04737253T patent/ATE517638T1/de not_active IP Right Cessation
-
2005
- 2005-07-26 IL IL169896A patent/IL169896A/en active IP Right Grant
-
2009
- 2009-04-09 US US12/420,864 patent/US7892547B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,775 patent/US8097252B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05008222A (es) | 2005-10-05 |
| US20040241158A1 (en) | 2004-12-02 |
| AU2004213752A1 (en) | 2004-09-02 |
| JP2006518737A (ja) | 2006-08-17 |
| CN1767860A (zh) | 2006-05-03 |
| EP1587550B1 (de) | 2011-07-27 |
| WO2004074434A3 (en) | 2005-03-17 |
| US20110117010A1 (en) | 2011-05-19 |
| EP1587550A2 (de) | 2005-10-26 |
| JP4874090B2 (ja) | 2012-02-08 |
| US20090238757A1 (en) | 2009-09-24 |
| CA2514277C (en) | 2015-01-20 |
| IL169896A (en) | 2011-03-31 |
| AU2004213752B2 (en) | 2008-10-23 |
| IL169896A0 (en) | 2007-07-04 |
| CA2514277A1 (en) | 2004-09-02 |
| WO2004074434A2 (en) | 2004-09-02 |
| US7534431B2 (en) | 2009-05-19 |
| US8097252B2 (en) | 2012-01-17 |
| US7892547B2 (en) | 2011-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE517638T1 (de) | Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln | |
| SG155054A1 (en) | Human anti- neutralizing antibodies as selective pathway inhibitors | |
| MEP31508A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| ATE450251T1 (de) | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung | |
| ATE443260T1 (de) | Kontrastmittel und verfahren zum imaging von naaldase oder psma | |
| NO20045521L (no) | Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
| EA200701036A1 (ru) | Лактамные соединения и их применение в качестве фармацевтических препаратов | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| BRPI0411241A (pt) | agentes terapêuticos úteis para o tratamento de dor | |
| DE602005021534D1 (de) | Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| ME00226B (me) | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade | |
| CY1109868T1 (el) | Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c | |
| DE60319083D1 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug | |
| ATE445644T1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
| ATE497763T1 (de) | Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen | |
| DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| ATE247130T1 (de) | Inhibitoren für den urokinaserezeptor | |
| BR0313019A (pt) | Compostos que se ligam a p-selectina | |
| ATE420162T1 (de) | Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen | |
| DE602005024690D1 (de) | Verfahren und verbindungen zum nachweis von medizinischen erkrankungen | |
| DE60041266D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |